KCNN1 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, our results are rather limited to a specific type of leukemia and our data imply that SK/IK channel inhibitors could be used to slow down the proliferation and spreading of CML K562 cells that express functionally active SK2, SK3 and IK channels in the plasma membrane.